Department of Surgery, Division of Trauma, Emergency Surgery and Surgical Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
J Surg Res. 2012 Dec;178(2):851-9. doi: 10.1016/j.jss.2012.07.023. Epub 2012 Jul 26.
We have previously demonstrated that pretreatment and posttreatment of animals with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, can improve survival in a mouse model of lipopolysaccharide (LPS)-induced severe shock. This study was designed to assess whether SAHA affects LPS/Toll-like receptor 4 signaling through acetylation of heat shock protein 90 (HSP90) and degradation of its client protein interleukin-1 receptor-associated kinase 1 (IRAK1).
RAW264.7 cells were exposed to LPS (1 μg/mL) for 2 h, followed by treatment with SAHA (10 μM) or geldanamycin (3 μM), an inhibitor of HSP90. Sham (no SAHA, no LPS) macrophages served as a control. The cells were harvested at different time points, and time zero served as the reference point.
LPS dramatically increased protein expression of myeloid differentiation factor 88 and IRAK1, and stimulated nuclear translocation of nuclear factor κB, leading to an increases of gene expression and protein production of tumor necrosis factor α and interleukin-6. Treatment with SAHA significantly attenuated these LPS-stimulated alterations. LPS or SAHA did not change the levels of HSP90 protein, but immunoprecipitation studies demonstrated that SAHA treatment enhanced acetylation of HSP90, and increased the dissociation of IRAK1, compared to the LPS control.
SAHA suppresses LPS/Toll-like receptor 4 signaling in LPS-stimulated macrophages through multiple potential mechanisms. It inhibits the function of HSP90 through hyperacetylation of the chaperone protein, which results in dissociation and degradation of the client protein IRAK1 and, at least in part, leads to a decrease in nuclear translocation of nuclear factor κB and attenuation of key proinflammatory cytokine expression.
我们之前的研究表明,组蛋白去乙酰化酶抑制剂 SAHA 预处理和后处理动物,可以改善脂多糖(LPS)诱导的严重休克小鼠模型的存活率。本研究旨在评估 SAHA 是否通过 HSP90 的乙酰化和其客户蛋白白细胞介素-1 受体相关激酶 1(IRAK1)的降解来影响 LPS/Toll 样受体 4 信号。
RAW264.7 细胞暴露于 LPS(1 μg/mL)2 h 后,用 SAHA(10 μM)或 geldanamycin(3 μM)处理,后者是 HSP90 的抑制剂。未处理 SAHA、未处理 LPS 的巨噬细胞作为对照。在不同时间点收获细胞,以时间零作为参考点。
LPS 显著增加髓样分化因子 88 和 IRAK1 的蛋白表达,并刺激核因子 κB 的核转位,导致肿瘤坏死因子 α 和白细胞介素-6 的基因表达和蛋白产生增加。SAHA 治疗显著减弱了这些 LPS 刺激的改变。LPS 或 SAHA 未改变 HSP90 蛋白水平,但免疫沉淀研究表明,与 LPS 对照相比,SAHA 处理增强了 HSP90 的乙酰化,并增加了 IRAK1 的解离。
SAHA 通过多种潜在机制抑制 LPS 刺激的巨噬细胞中的 LPS/Toll 样受体 4 信号。它通过使伴侣蛋白过度乙酰化来抑制 HSP90 的功能,导致客户蛋白 IRAK1 的解离和降解,至少部分导致核因子 κB 的核转位减少和关键促炎细胞因子表达的减弱。